Showing 1 - 5 results of 5 for search 'Emeline Perrial', query time: 0.02s Refine Results
  1. 1
    Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients.

    Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients. by Virginie Marcel, Frédéric Catez, Caroline M Berger, Emeline Perrial, Adriana Plesa, Xavier Thomas, Eve Mattei, Sandrine Hayette, Pierre Saintigny, Philippe Bouvet, Jean-Jacques Diaz, Charles Dumontet

    Published 2017-01-01
    Get full text
    Article
  2. 2
    End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy

    End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy by Pierre Sesques, Lionel Karlin, Emmanuel Massy, Alizée Maarek, Guillaume Aussedat, Anne Lazareth, Camille Golfier, Fadhela Bouafia-Sauvy, Helene Lequeu, Dana Ghergus, Violaine Safar, Emmanuelle Ferrant, Emmanuel Bachy, Hervé Ghesquières, Cyrille B. Confavreux, Delphine Demangel, Emeline Perrial, Charles Dumontet

    Published 2024-10-01
    Get full text
    Article
  3. 3
    The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer

    The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer by Jean-Marc Barret, André Nicolas, Anne Jarry, Olivier Dubreuil, Didier Meseure, Tilda Passat, Emeline Perrial, Cécile Deleine, Gabriel Champenois, Solenne Gaillard, Emilie Duchalais, Isabelle Ray-Coquard, Mehdi Lahmar, Charles Dumontet, Jaafar Bennouna, Céline Bossard, Sergio Roman-Roman, Jean-François Prost

    Published 2021-04-01
    Get full text
    Article
  4. 4
    A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models

    A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models by Kamel Chettab, Kamel Chettab, Chantel Fitzsimmons, Alexey Novikov, Morgane Denis, Morgane Denis, Capucine Phelip, Doriane Mathé, Pierre Antoine Choffour, Sabine Beaumel, Eric Fourmaux, Patrick Norca, David Kryza, Anne Evesque, Lars Petter Jordheim, Emeline Perrial, Eva-Laure Matera, Martine Caroff, Jerome Kerzerho, Charles Dumontet, Charles Dumontet

    Published 2023-05-01
    Get full text
    Article
  5. 5
    A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma

    A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma by Emilie Decaup, Emilie Decaup, Emilie Decaup, Cédric Rossi, Cédric Rossi, Cédric Rossi, Cédric Rossi, Pauline Gravelle, Pauline Gravelle, Pauline Gravelle, Pauline Gravelle, Camille Laurent, Camille Laurent, Camille Laurent, Camille Laurent, Julie Bordenave, Julie Bordenave, Julie Bordenave, Marie Tosolini, Anne Tourette, Emeline Perrial, Charles Dumontet, Mary Poupot, Mary Poupot, Mary Poupot, Christian Klein, Ariel Savina, Jean-Jacques Fournié, Jean-Jacques Fournié, Jean-Jacques Fournié, Christine Bezombes, Christine Bezombes, Christine Bezombes

    Published 2019-08-01
    Get full text
    Article

Search Tools: